Clinical Trials Logo

Cocaine Dependence clinical trials

View clinical trials related to Cocaine Dependence.

Filter by:

NCT ID: NCT00249444 Completed - Depression Clinical Trials

Mirtazapine for Treating Cocaine Dependent Individuals Who Also Suffer From Depression

Start date: May 2006
Phase: Phase 2
Study type: Interventional

Many substance dependent individuals also suffer from depression. Past research suggests that antidepressant medication is helpful in treating such individuals. This study will determine the effectiveness of mirtazapine, an antidepressant medication, in treating cocaine dependent individuals who also suffer from depression. This study includes free treatment for cocaine dependence that includes medication and a behavioral intervention.

NCT ID: NCT00240227 Terminated - Alcoholism Clinical Trials

Prazosin for ETOH or Cocaine Craving

Start date: April 2004
Phase: N/A
Study type: Interventional

This double-blind placebo controlled crossover pilot trial will test the hypothesis that prazosin, an alpha-1 adrenergic receptor antagonist, reduces craving for their drug of choice in cocaine-dependent and alcohol-dependent veterans. Both the study medication period and the placebo period are each 4 weeks in duration.

NCT ID: NCT00240110 Completed - Bipolar Disorder Clinical Trials

Valproate Efficacy in Cocaine-Bipolar Comorbidity

Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This proposal will test the efficacy of a promising pharmacological approach for the treatment of comorbid cocaine dependence and bipolar disorder. We propose a randomized, double blind, placebo controlled 12-week trial to test the efficacy of Divalproex sodium (Valproate) plus treatment as usual compared to placebo plus treatment as usual in decreasing cocaine use and stabilizing mood symptoms among patients with comorbid cocaine dependence and bipolar disorder. Treatment as usual includes the use of lithium carbonate for mood stabilization plus supportive psychosocial treatment.

NCT ID: NCT00227812 Completed - Clinical trials for Depressive Disorder, Major

Integrated Treatment for Cocaine and Mood Disorders - 1

Start date: April 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test whether cognitive behavioral therapy and bupropion hydrochloride will help cocaine users, who are depressed, reduce or end their cocaine use and improve their mood.

NCT ID: NCT00227123 Completed - Bipolar Disorder Clinical Trials

A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence

Start date: October 2002
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether quetiapine or risperidone are effective in treating mood symptoms, drug cravings and use in bipolar disorder with concurrent cocaine or methamphetamine dependence.

NCT ID: NCT00223236 Completed - Cocaine Dependence Clinical Trials

Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence

Start date: July 2010
Phase: Phase 3
Study type: Interventional

The purpose of this research is to determine if a citicoline supplement is associated with a reduction in cocaine use and craving in patients with bipolar disorder (a mental disorder marked by alternating periods of mania and depression) or schizoaffective disorder/bipolar type (a psychotic disturbance in which there is a mixture of schizophrenic and manic-depressive symptoms) and cocaine abuse/dependence. This research also wants to explore if citicoline supplements are associated with greater improvement in symptoms of mania and on memory and cognition (the mental faculty of perception, reasoning, and judgement) in these patients.

NCT ID: NCT00223210 Completed - Bipolar Disorder Clinical Trials

An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence

Start date: November 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if quetiapine add-on therapy is associated with a decrease in cocaine use and craving and a greater improvement in mood.

NCT ID: NCT00218660 Completed - Alcoholism Clinical Trials

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1

Start date: April 1998
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see whether naltrexone is safe and useful in preventing alcohol relapse, as well as in decreasing craving for alcohol in people with a diagnosis of alcohol and cocaine dependence. Naltrexone is approved by the Food and Drug Administration (FDA) for the treatment of alcohol dependence. However, the medication was not approved as yet at the dosage we will use in this study. The dosage we will use for the study (150 mg), is greater than the recommended dosage from the Physician's Desk Reference (50mg). Unlike other medicines (like Antabuse) useful in the treatment of alcohol dependence, naltrexone will not make you sick if you drink alcohol. Rather, people who are taking this medication have reported that it helps decrease the pleasure associated with drinking for them. This study is being conducted because the medication (Naltrexone) has not been well studied in people with both alcohol and cocaine dependence, so it is still investigational. We believe that if we can reduce alcohol consumption through naltrexone and psychotherapy, this may lead to reduced cocaine use. We are also conducting this study to test two different types of psychotherapy as a method for reducing cocaine and alcohol use. One type of psychotherapy, CBT, is designed to help people learn to cope with situations that put them at high risk for relapse to cocaine and/or alcohol use. The other type of psychotherapy, BRENDA, will use focuses on strengthening motivation to recover from cocaine and/or alcohol use, and on developing techniques to handle possible barriers to recovery. We seek to enroll 300 patients in the study.

NCT ID: NCT00218569 Completed - Alcohol Dependence Clinical Trials

Combined Treatment for Cocaine-Alcohol Dependence - 1

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine whether Naltrexone and cognitive behavioral therapy can be helpful in patients who want to stop using cocaine and alcohol.

NCT ID: NCT00218491 Completed - Cocaine Dependence Clinical Trials

Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1

NAC
Start date: November 2005
Phase: Phase 2
Study type: Interventional

Currently, no effective drug treatment exists for cocaine dependence. Glutamate levels are disrupted with long-term cocaine use. N-acetyl cysteine (NAC) is a drug that is metabolized by the body to form cysteine, an active compound that normalizes glutamate levels. The purpose of this study is to determine the safety and effectiveness of NAC in treating cocaine dependent individuals.